Abcam, ab261822, Human EEA1 knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
EEA1 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 13. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 13,
Antibiotic resistance:Puromycin 1µg/mL,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-EEA1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EEA1 (Early Endosome Antigen 1) is an important protein involved in endosomal trafficking with a molecular weight of approximately 162 kDa. It is a cytoplasmic protein expressed in various cell types acting mainly as an endosome marker. This protein contains a FYVE domain which facilitates binding to phosphatidylinositol 3-phosphate on endosomal membranes. EEA1 also interacts with Rab5 a small GTPase contributing to the fusion of early endosomes.
Biological function summary
EEA1 plays a significant role in early endosomal pathways facilitating endocytic vesicle fusion. EEA1 does not usually work alone; it functions as part of a larger complex involving other endosomal proteins. This protein acts as a tethering molecule which stabilizes the interaction of vesicles with endosomes. By anchoring vesicles EEA1 ensures the correct delivery and sorting of cargo within the cell which is important for cellular homeostasis and signaling.
Pathways
EEA1 contributes to the endocytic pathway and receptor recycling. It ensures proper functioning of the endocytic recycling of receptors such as the epidermal growth factor receptor (EGFR). EEA1-mediated tethering is vital for these pathways and it works closely with proteins like Rab5 which regulate endocytic trafficking. Through these interactions EEA1 affects cellular processes by controlling the flow of signaling receptors and other molecules within the cell.
EEA1 dysfunction is linked to neurodegenerative diseases and cancer. Abnormalities in its expression or function can disrupt endosomal trafficking leading to cellular stress and disease. For example in Alzheimer's disease impaired endosomal function involving EEA1 can contribute to amyloid-beta accumulation. In cancer altered EEA1 activity may contribute to aberrant receptor signaling which can promote unchecked cell division. The interplay with proteins like EGFR demonstrates EEA1's importance in maintaining cellular health and response mechanisms.